TickerTalks
Browse all tickers →
TickerTalks›$PFE
PFPFE

Pfizer Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 5% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (659/wk), no spike
$PFE·$169B·Drug Manufacturers - General·Healthcare
$29.58+0.5%YTD+13.6%1Y+22.1%
Price updated 7h ago·X counts updated 12d ago
PFPFE
$PFEPfizer Inc.
$29.58+0.48%659 posts
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $PFE on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

659X posts · last 7 days
Sep 29Oct 4
Bullish sentimentAI analysisGenerated by AI from underlying data7 posts analyzed · as of 2026-09-16

Pfizer chatter is thin but positive. Morningstar has $PFE on its 10 best dividend stocks list, and Pendle just launched tokenized-dividend markets pairing $NVDA and $PFE through year-end on Robinhood. One poster claims Pfizer has the ingredients for an MRNA-style move. A separate DOPAMEME memecoin thread is riding the pairing frenzy. No bear voice.

Read what X is saying about $PFE

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $PFE — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

A 6%-yielding big pharma with growth quietly returning — 20x on a franchise still working off COVID-vaccine comparisons.

Pfizer is the global big-pharma franchise most people blame for the post-COVID vaccine drawdown — now trading at a 6% dividend yield as the business works through hard comparisons. Growth has quietly returned.

  • Revenue growth is positive again: Q1 2026 at $14.5B was up 5.4% YoY after -1.2%, -5.9%, and +10% in the prior quarters — the COVID-vaccine base-effect is behind the P&L and the base business is growing again.
  • Earnings beats are consistent and sizable: last four quarters at +37%, +16%, +4%, and +13% — the cost program is landing, which supports the $2.97 2026 EPS consensus against a $27.80 stock, or ~9.5x forward.
  • The 6% dividend is the whole alternative: at 20x trailing on 69% gross margins and 23% operating margins, the setup is cheap for a quality pharma — the issue has always been the shelf life of the GLP-1-adjacent and oncology pipeline.

Nov 3 Q3 earnings with the oncology franchise plus LITFULO ramp above estimates extends the quiet re-rate; a guide cut or a weak oncology print and the dividend becomes the only reason to hold.

Agrees with X sentimentX is thin but positive on PFE as a dividend-staple pick and the mRNA-upside optionality — the real signals are the recent revenue inflection and the LITFULO data on nonsegmental vitiligo. The DOPAMEME memecoin thread is unrelated noise.

What to watch: Nov 3 Q3 earnings — core revenue growth above 5% ex-COVID, LITFULO uptake, and any guidance refresh on the 2027/2028 patent-cliff cushion from oncology. A guide cut on the cost-cutting program is what breaks the current coil.

On the calendar: 2026-11-03 — Q3 2026 earnings

Read the AI verdict on $PFE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes vaccines, oncology drugs, and small-molecule medicines while rebuilding revenue after COVID product declines.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $PFE.

Drug Manufacturers - General · Healthcare

No material change from last week — GLP-1 duopoly (LLY/NVO) drives premium valuations while patent-cliff management defines the rest: ABBV migraine franchise win strengthens post-Humira portfolio.

What this means for $PFE

Neutral — Makes vaccines, oncology drugs, and small-molecule medicines while rebuilding revenue after COVID product declines.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+14.5%YTD
+36.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
19.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
8.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
23.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
8.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
69.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$0.77$0.68+12.9%
Q1 2026May 5, 2026$0.75$0.72+3.9%
Q4 2025Feb 3, 2026$0.66$0.57+16.4%
Q3 2025Nov 4, 2025$0.87$0.63+37.4%
Next earningsTue, Nov 3·consensus EPS $0.73

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$14.5B+5.4%67.3%27.9%$0.47$2.2B
Q4 FY25$17.6B-1.2%70.0%21.0%$-0.29$4.5B
Q3 FY25$16.7B-5.9%74.9%21.3%$0.62$4.0B
Q2 FY25$14.7B+10.3%64.3%24.4%$0.51$-1.2B

Forward consensus

5-year forecast · up to 22 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$62.2B$61.3B – $63.7B$2.97$2.88 – $3.0919
FY27$59.8B$58.5B – $61.0B$2.90$2.76 – $3.0918
FY28$54.8B$51.6B – $58.1B$2.49$1.60 – $3.0122
FY29$52.9B$51.4B – $54.7B$2.36$2.27 – $2.4614
FY30$53.2B$51.8B – $55.1B$2.44$2.35 – $2.5511

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.95%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+5.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+11.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β0.285-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyAug 12Albert BourlaCEO38.0K sh$1.0MSellAug 5Jennifer B. DamicoSVP & Controller3.3K sh$83KBuyAug 5Mortimer J BuckleyDirector37.6K sh$960KBuyAug 5Ronald E BlaylockDirector39.2K sh$999KSellJun 9Jennifer B. DamicoSVP & Controller2.0K sh$51K
+ 37 other (37 awards) in window

See when $PFE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 283
AI summary

Cecile Guegan, Executive Vice President of Pfizer Inc., filed a Form 3 on August 28, 2026, reporting beneficial ownership of 149,505 shares of common stock plus stock appreciation rights (SARs) on approximately 104,129 underlying shares across multiple grants at strike prices ranging from $25.75 to $45.96, exercisable between 2027–2031. Routine insider ownership disclosure following a change in reporting status. No market significance.

8-KPress release / Reg FDJun 188-K — Item 7.01: Press release / Reg FD
AI summary

Pfizer reaffirmed its full-year 2026 financial guidance on June 18, 2026, concurrent with the CFO departure announcement. Guidance is unchanged: revenues of $59.5–$62.5 billion and Adjusted Diluted EPS of $2.80–$3.00, consistent with the December 2025 introduction and May 5, 2026 Q1 call reaffirmation. The same-day guidance reaffirmation alongside the CFO transition is designed to signal management confidence in the financial outlook and contains investor concern from the leadership change. Stable outlook — Pfizer is holding guidance range despite a CFO departure mid-year.

8-KOfficer or director changeJun 188-K — Item 5.02: Officer or director change
AI summary

Pfizer CFO Dave Denton notified the company on June 16, 2026 that he will resign effective August 15, 2026 to pursue a role in consumer goods outside pharmaceuticals, with no disagreement over Pfizer's financial or operating results. Cecile Guegan (55), SVP Finance, Global Biopharmaceutical Business (Pfizer since 2005, current role since 2022), will serve as Interim CFO from August 16, 2026 while a comprehensive permanent search is conducted. A CFO departure mid-year is material for a large-cap pharma navigating post-COVID product portfolio transitions; the same-day guidance reaffirmation (see companion 8-K) was filed simultaneously to offset investor concern.

3/ANew insider — initial holdingsApr 273/A
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3/A (amended) for PFE on 2026-04-27, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

8-KShareholder voteApr 278-K — Item 5.07: Shareholder vote
AI summary

PFE held its Annual Meeting of stockholders around 2026-04-27 (8-K Item 5.07). Stockholders elected 11 directors to the board. Independent auditor ratification was approved. Routine governance event — monitor for unusually high withhold votes as an activist signal.

+ 12 other (2 13Fs · 2 10-Qs · 2 earnings 8-Ks · 2 11-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?fool.com·13h agoNovavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady247wallst.com·15h agoModerna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put247wallst.com·17h ago6 Blue Chip Stocks Trading Well Below Their Highsfool.com·23h agoModerna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher247wallst.com·2d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$OGN$LLY$NVO$JNJ$ABBV$MRK$BMY$AMGN
Voices on X · top 7 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport